16:52:03 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-03-21 Ordinarie utdelning FLUO 0.00 DKK
2024-03-20 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-03-22 Ordinarie utdelning FLUO 0.00 DKK
2023-03-21 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning FLUO 0.00 DKK
2022-05-18 Årsstämma 2022
2022-03-30 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning FLUO 0.00 DKK
2021-02-26 Bokslutskommuniké 2020
2021-02-09 Årsstämma 2021
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-14 Kvartalsrapport 2020-Q2
2020-05-27 Kvartalsrapport 2020-Q1
2020-04-09 Ordinarie utdelning FLUO 0.00 DKK
2020-04-08 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-05-31 Kvartalsrapport 2019-Q1


ListaFirst North Stockholm
FluoGuide är ett danskt bolag verksamma inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.
2023-08-30 08:05:00

Copenhagen, Denmark, 30 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 June 2023. The Q2 report is available as an attached document to this press release and on FluoGuide’s website.

In Q2 2023, FluoGuide prepared completion of all three clinical phase II trials of FG001 in different types of cancers. Positive results or interim results in all indications and the forthcoming topline result of the phase IIb trial in aggressive brain cancer put FluoGuide in a uniquely promising position. Financial flexibility enables the company to fully capitalize on the good clinical results.

FluoGuide had no revenue for the period and posted a net result of TDKK -7,139 (TDKK -5,749) for the period 1 January to 30 June 2023. The financial result for the period is in line with the Company's development plans.

SummaryQ2 23Q2 22YTD 2023YTD 20222022
DKK thousands1-Apr-231-Apr-221-Jan-231-Jan-221-Jan-22
Net Revenue-----
Operating result-8,656-7,514-20,302-12,942-32,461
Net result-7,139-5,749-16,674-9,701-27,340
Cash and bank8,06439,1368,06439,13626,013
Result per share (DKK) *)-0.60-0.49-1.41-0.82-2.33
Solidity (%) **)83%92%83%92%90%


  • FluoGuide provides update on strong clinical trial progress
  • FluoGuide announces positive topline results from phase IIa trial of FG001 in lung cancer
  • FluoGuide announces positive interim results from phase IIa trial of FG001 in head & neck cancer


  • FluoGuide completes a Directed Share Issue raising SEK 15 million. Investors received one warrant per share to exercise in the period 27 November to 1 December
  • FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer
  • FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer

For further information, please contact:
Morten Albrechtsen, CEO,
FluoGuide A/S
+45 24 25 62 66,

Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

About FluoGuide
FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. This improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company has published key results on the efficacy of FG001 as well as showing it was well tolerated and safe from a proof-of-concept clinical study (phase I/IIa) in patients with aggressive brain cancer (high grade glioma) that undergo surgery. A phase IIb trial in aggressive brain cancer is ongoing to obtain valuable information to design the phase III trial. This IIb trial has completed patient enrollment and treatment, and data complication is ongoing. In addition, FluoGuide has demonstrated effect of FG001 in lung and head & neck cancer, topline and positive interim result, respectively. A trial in meningioma and glioma is commencing.
For more information on the Company, please visit www.fluoguide.com